| Purpose:This study aimed to observe the primary response of apatinib in patients with advanced or relapsed ovarian cancer who present with chemoresistant.Methods:Ten patients with advanced or relapsed ovarian cancer who present resistance to previous chemotherapy following primary suboptimal surgery were retrospectively analyzed.Oral mesylate apatinib tablet(250mg/d)was administered.The disease control rate(DCR),objective response rate(ORR)and the adverse events were assessed based upon the RECIST 1.1 and GCOG criteria,and together with serum cancer antigen 125(CA125)and human epididymis protein 4(HE4).Result:All the 10 patients underwent primary suboptimal surgery followed by taxane and platinum-based chemotherapy.Among them eight patients(8/10)had at least one recurrence,while the remaining two showed chemoresistance against the fist-line chemotherapy.All the patients appeared chemoresistance before taking apatinib.After the administration of apatinib for eight weeks,the DCR and ORR were 70%(7/10)and 70%(7/10),respectively.No fatal adverse events related to apatinib were noticed during the treatment period.The most common adverse event(AE)was hypertension(6/10).Conclusions:Apatinib seems to provide a promising option for chemoresistant ovarian cancer patients,and showed high response of DCR and ORR along with relatively controllable and tolerable AEs. |
PDF Full Text Request